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Edited by Sandro SonninoAbstract Phosphorylcholine (PC) is a classical ligand of C-
reactive protein (CRP), a clinically important acute phase
protein. In search of new ligands, CRPs were affinity-purified
from several pathological samples, which exhibited distinct
molecular variants induced in different diseases. Both glycosy-
lated and non-glycosylated CRPs showed calcium-independent
differential-binding to Staphylococcus aureus cell-surface Pro-
tein A. CRP possesses separate binding sites for Protein A and
PC with different binding constants. We have demonstrated that
Protein A is another ligand in addition to PC establishing an
extended definition of CRP. Protein A binding may impart
immunomodulatory roles of CRP in combating microorganisms
or other foreign materials.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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C-reactive protein (CRP) is a phylogenetically ancient and
highly conserved major acute-phase homopentameric plasma
protein. According to the classic definition of CRP, pro-
claimed in 1930, it binds specifically to phosphorylcholine (PC)
moiety of pneumococcal C-polysaccharide in a characteristic
calcium dependent manner [1]. Most of the reactivity of CRP
mediates through binding of surface structure of a number of
different microorganisms by complement activation. Although,
the gram-positive bacteria are generally resistant to comple-
ment-mediated lysis, CRP, after association with its ligands, is
able to opsonize these cells and thus facilitates the clearance of
encapsulated bacteria from the circulation [2,3]. Therefore, it is
worthwhile to search for new physiological ligands, which may
provide information on the specific biological roles of CRP.
CRP and immunoglobulin G (IgG) share many functions
like complement activation, opsonization and phagocytosis [4]
and also have similar type of amino acid composition, sug-* Corresponding author. Fax: +91-33-2473-5197/91-33-2472-3967.
E-mail addresses: cmandal@iicb.res.in, Chitra_mandal@yahoo.com
(C. Mandal).
Abbreviations: ABTS, 2,20-azino-bis(3-ethylbenzthiazoline-6-sulfonic
acid) ammonium salt; CRP, C-reactive protein; IgG, Immunoglobulin
G; PC, Phosphorylcholine; S. aureus, Staphylococcus aureus; SpA,
Staphylococcus aureus cell-surface Protein A
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ficity of Fc region of IgG with Staphylococcus aureus Protein A
(SpA), a 42 kDa well-characterized cell wall protein, has been
exploited in numerous immunochemical studies. Considering
the similarity between CRP and IgG, it is interesting to explore
whether Protein A behaves as a ligand also for CRP.
Different molecular variants of CRP are reported to be in-
duced under different toxic aquatic conditions in fresh water
fishes [6–10]. Recently, we have convincingly demonstrated
that human CRP is glycosylated and distinct molecular vari-
ants are induced in several pathological conditions [11].
The main aim of the current investigation is to explore the
ligand binding property of CRP for better assessment of the
structural aspects of this group of proteins. Therefore, CRPs
are purified in different pathological conditions (Table 1).
Subsequently, existence of distinct molecular variants have
been demonstrated with differential binding to Protein A,
which has been established as a new ligand for CRP. Existence
of separate binding sites and differential affinity of CRP for
Protein A and PC allowed us to propose an extended definition
of CRP.2. Materials and methods
Sera from patients (Table 1) showing detectable levels of CRP by
agglutination were used for experiments with the approval of Institu-
tional human ethical clearance committee. Informed consent was taken
from all individuals.
2.1. Purification and characterization of human CRP
CRPs were purified following a standard protocol as described by
Volanakis et al. [12,13]. Typically, human serum (approx. 4 ml) was
passed through a column of agarose beads (1 cm 5 cm) in the pres-
ence of Tris-buffered saline (TBS; 50 mM Tris/HCl and 150 mM
NaCl), pH 7.5, with CaCl2 (5 mM) to remove the serum amyloid-P
component. It was immediately applied to Sepharose–PC (1 cm 10
cm) affinity matrix, washed with TBS (20 mM Tris/HCl) and CaCl2 (10
mM), pH 7.5 and bound protein was eluted with EDTA (10 mM)
containing CaCl2 (1 mM). Protein fractions were pooled, dialyzed
against TBS (20 mM Tris/HCl), before adjusting the calcium concen-
tration to 10 mM, and were allowed again to bind to another Sepha-
rose–PC affinity matrix. The column was washed with TBS containing
CaCl2 (10 mM) and pure CRP was eluted with PC (2 mM) in TBS (20
mM Tris/HCl), pH 7.5, containing CaCl2 (0.5 mM). The eluted protein
was extensively dialyzed against HEPES (20 mM) with saline con-
taining EDTA (2 mM), followed by same buffer without EDTA and
stored at )20 C. Concentration of CRP was measured by a compet-
itive-ELISA using polyclonal anti-human CRP antibody with refer-
ence to a standard curve generated using known concentrations of
CRP [14].
Purified CRPs were analyzed by native- (5%) [15], and SDS–PAGE
(7.5–10%) [16] under reducing and non-reducing conditions. Westernblished by Elsevier B.V. All rights reserved.
Table 1
Concentration and molecular profile of CRPs
No. Clinical samples CRP in crude serum Fold increaseb Sugar@ Sialic acid$ Linkage specific sialic acid#
Agglutinationa Competitive ELISA
(lg/ml)
SNA MAA
1 Rheumatic fever +++ 17.0–42.4 34–84 1+ – ND ND
2 Alcoholic hepatitis + 35.2–58.3 70–116 3+ 1+ 1+ –
3 Acute appendicitis
(post surgery)
++ 55.0–62.4 110–124 1+ 2+ – 1+
4 Liver malignancy + 22.5–44.0 45–88 2+ 4+ – 4+
5 Snake bite +++ 39.3–47.2 79–94 3+ 2+ 3+ –
6 Rheumatoid arthritis
(RA)
+++ 53.3–67.0 106–134 2+ 1+ 2+ –
7 Brain abscess ++ 8.1–28.0 16–56 – – ND ND
8 Meningitis +++ 18.3–41.4 37–83 2+ 2+ – 2+
@; $; # The extent of glycosylation, sialylation and linkage specific sialic acid was determined (Section 2.1) and graded by ‘+’ based on densitometric
scanning.
‘)’, Absence of total sugars and sialic acid; ND, not determined.
a Polystyrene latex particles coated with monoclonal anti-CRPantibodies were incubated with crude serum and graded as weak (+), medium (++) and
strong (+++), depending on degree of visible agglutination.
b Fold increase was calculated considering 0.5 lg/ml as normal level.
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anti-human IgG antibodies.
In addition, two ELISA were used for further detection of any
possible contamination of human IgG in the CRP sample. Human IgG
(0–500 ng/100 ll/well) were separately coated on the same 96-well
ELISA plate. After non-specific blocking, HRP-anti-human IgG was
added, washed extensively and bound complex was detected by 2,20-
azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) ammonium salt
(ABTS) and read at OD405nm by ELISA reader (Win Read V.2.1,
Anthos Labtec, UK). A standard graph was generated by plotting
different concentrations of human IgG vs OD405nm; linearity was ob-
served between 0 and 100 ng concentrations of IgG. In parallel, under
identical conditions, CRP (250 ng/100 ll/well) was coated separately in
the same plate and processed similarly.
Additionally, a known amount 0, 5, 10, 25, 50 and 100 ng of human
IgG was mixed with 250, 245, 240, 225, 200 and 150 ng of CRP, re-
spectively, maintaining final protein concentration at 250 ng and
coated on wells (250 ng/100 ll/well), blocked and HRP-anti-human
IgG was added. The wells were processed as described above.
The degree of glycosylation, sialylation and linkage specific sialic
acid was detected using equal amounts of CRP by DIG-glycan de-
tection and differentiation kits according to manufacturer’s instruc-
tions (Roche Molecular Biochemicals, Cat Nos. 1142372 and 1210238,
respectively). To reconfirm the presence of sugars in the induced CRPs,
they were deglycosylated using deglycosylation kit (Roche Molecular
Biochemicals, Cat Nos. 1836552 and 1347101) and analyzed by SDS–
PAGE.
2.2. ELISA for CRP binding to Protein A
The binding of both glycosylated and non-glycosylated CRPs with
Protein A was analyzed by a two-step ELISA. The microtitre plate was
coated with fixed or increasing concentration of CRPs by keeping
overnight, washed, blocked with BSA (2%, TBS–BSA) at 25 C for 2 h
and incubated with HRP–Protein A (dilution 1:10,000) for 30 min at
37 C. After extensive washing the bound complex was detected by
ABTS and read at OD405nm by ELISA reader.
In order to quantitate the contribution of IgG contamination (if any)
in CRP, in its Protein A binding, another ELISA was designed, in
which human IgG (0–500 ng/100 ll/well) were coated on a 96-well
ELISA plate and HRP–Protein A was added. In parallel, under
identical condition, CRP (250 ng/100 ll/well) was coated separately in
the same plate and processed similarly.
2.3. ELISA forCRPbinding toProteinA in presence of PCand vice versa
In order to distinguish the binding sites of CRP for both PC and
Protein A, an inhibition study was performed. Either fixed amount of
CRP pre-incubated with PC (50–150 mM in 0.5 mM CaCl2) were
immobilized onto the microtitre wells or PC was allowed to bind with
CRP-coated wells at 4 C overnight, washed and incubated with HRP–Protein A. In parallel, PC and HRP–Protein A were added together to
the CRP-coated wells and processed as above.
2.4. Binding of CRPs to Protein A–sepharose 4B
CRPs were iodinated [18] and fixed amounts of 125I-CRPs were
separately incubated with Sepharose–Protein A (20 ll) in presence of
CaCl2 (0–50 mM) overnight at 4 C. Equal volume of buffer lacking
CaCl2 was used as control.
To assess the nature of CRP–Protein A binding, a fixed amount of
Sepharose–Protein A matrix (20 ll) was incubated with increasing
amounts of 125I-CRPs in the presence or absence of CaCl2 (0.5 mM)
overnight at 4 C. Un-conjugated Sepharose-4B along with CRP pre-
incubated with galactose (50 mM) was used as control to exclude the
non-specific binding. Measurements were done in triplicates. The
binding constants were calculated from the Scatchard plot [19]. For
comparison of CRP–Protein A binding with CRP–PC, Sepharose–
Protein A was replaced with Sepharose–PC and processed similarly.
2.5. Binding of CRP to S. aureus bacterial cells
To demonstrate the binding of CRP to Protein A, S. aureus, rich
source of cell surface protein A (SpA) was used. 125I-CRPs, with or
without pre-incubation with PC (150 mM in TBS–CaCl2) to block the
PC binding sites at 4 C overnight, were allowed to react with different
amounts of bacterial cells (OD600nm ¼ 0:2–0.7) at 37 C for 30 min,
washed with TBS–BSA and bound radioactivity was measured.
Similarly, 125I-CRPs were pre-incubated with Protein A (molar ratio
of CRP/Protein A¼ 1:5) to block all the Protein A binding sites on
CRPs and incubated with the bacteria (OD600nm ¼ 0:5), washed and
the bound counts for Protein A-incubated-CRP were compared with
the counts exhibited by free CRP.
2.6. Flow cytometric analysis of binding of FITC-CRP to S. aureus
Cells (OD600nm ¼ 0:5 in TBS–BSA) were incubated with FITC-
CRPs (0.1–50 lg/ml) or FITC-CRPs pre-incubated with Protein A at
37 C for 30 min, washed twice, fixed with 4% paraformaldehyde and
analyzed on a Becton Dickinson FACScan using CELL QUEST
software. Only Cells, FITC-BSA or cells incubated with unconjugated
CRP served as controls.3. Results
3.1. Purification and molecular characterization of CRPs
CRPswerepurified separately from individual patients having
several pathological conditions (Table1).Crude sera (lane 1)and
serially purified fractionswere electrophoretically analyzed (Fig.
1A). Amongst the major proteins found in the eluate from aga-
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(lane 3) and, therefore, considered as calcium binding proteins.
Single band inPCelution from2ndPCcolumnwas taken as pure
CRP (lane 4). Single band inWestern blotwith anti-humanCRP
further confirmed its homogeneity (lane 7). As assayed by im-
munoblotting of the gel using polyclonal anti-human IgG anti-
serum, the preparation of purified CRP showed no detectable
amounts of IgG confirming its absence as demonstrated by the
lackofbindingwithanti-humanIgG(lane5) as compared to lane
6 in which standard human IgG showed strong bands.
No IgG (lane 4) was detected even with higher amount of
CRP, when pure human IgG (lane 1) along with three different
concentrations of CRPVL (lanes 2–4) was analyzed on SDS–
PAGE (Fig. 1B). In order to examine any contamination of
human IgG in the CRP sample, an ELISA was performed in
which CRP (250 ng) was allowed to bind with anti-humanFig. 1. Purification and characterization of CRPs. (A) Electrophoretic analysi
with rheumatoid arthritis were electrophoretically analyzed on a SDS–PAG
column; lane 3, EDTA eluates from 1st PC column and lane 4, PC eluates f
eluted fraction from a patient (lane 5) and standard human IgG (lane 6) prob
murine anti-human CRP and detected by HRP-anti-murine IgG. (B) An incre
4, respectively), along with human IgG (1 lg/well, lane 1) were analyzed by
Following analysis were carried out using purified CRPs (1 lg/lane or spot). B
(C)–(D) Native and SDS–PAGE. CRPs were electrophoretically analyzed. (E
nitrocellulose strips and processed as described in Section 2.1. Columns 9 a
Detection of a2-6 and a2-3 linked sialic acid. CRPalcoholic hepatitis, CRPacute append
were analyzed by DIG glycan differentiation kit using a2-6 (SNA) and a2-3 (M
treatment with N-glycosidase F. A representative profile of a glycosylated CR
2) at 37 C overnight were electrophoresed (Section 2.1). The upper band inIgG. Under identical condition, negligible absorbance
(OD405 nm ¼ 0:013 0:002) was observed in CRP-coated wells
in comparison with equal amount of pure IgG was coated on
the same plate (Fig. 2A). Considering the limit of sensitivity of
this ELISA, the OD in CRP coated wells may be considered as
the basal level and IgG contamination would be less than 1%
(Fig. 2A). In parallel, when a known amount 0, 5, 10, 25, 50
and 100 ng of human IgG was mixed with 250, 245, 240, 225,
200 and 150 ng of CRP, respectively, maintaining the final
protein concentration at 250 ng, IgG alone or IgG-CRP mix-
ture showed almost same OD405 nm (Fig. 2A).
The induced CRP levels, as determined by ELISA from
crude serum, varied significantly from 8–67 lg/ml of serum
(Table 1), corresponded to 16–134-fold increase above the
normal level (0.5 lg/ml) confirming that CRP was an acute
phase reactant in these pathological conditions.s. Equal amounts of serially purified fractions from serum of a patient
E (10%). Lane 1, crude serum; lane 2, unbound fraction from agarose
rom 2nd PC column; Western blotting of equal amount (14 lg) of PC
ed with HRP-anti-human IgG; lane 7, PC eluted fraction probed with
asing amount of purified human CRPVL (1, 2.5, 5 lg/well in lanes 2, 3,
SDS/PAGE. Gel was fixed and stained for protein with silver nitrate.
ands/spots 1–8 correspond to the CRPs in the same order as in Table 1.
)–(F) Detection of neutral sugar and sialic acid. CRPs were blotted on
nd 10 represent positive and negative controls, respectively. (G)–(H)
icitis, CRPlivermalignancy, CRPsnakebite, CRPRA, CRPmeningitis (columns 1–6)
AA) linked sialic acid binding lectins. (I) SDS–PAGE before and after
Pacute appendicitis before (lane 1) and after N-glycosidase F digestion (lane
lane 2 corresponds to N-glycosidase F (34.6 kDa).
Fig. 3. Binding of Protein A with CRP as detected by ELISA. CRP
(250 ng) coated wells were incubated with constant amount of HRP–
Protein A and binding was detected by ABTS (Section 2.2) and extent
of binding was compared. ‘+’ denotes extent of glycosylation (Table 1)
[11]. Inset. Different concentrations (0–4 lg/ml) of a CRPburn was
tested for Protein A binding.
Fig. 2. Evaluation of contaminating IgG (if any) in purified CRP by ELISA. (A) A known amount 0, 5, 10, 25, 50 and 100 ng of human IgG was
mixed with 250, 245, 240, 225, 200 and 150 ng of CRP, respectively, maintaining final protein concentration at 250 ng. The IgG alone () or IgG-
CRP mixture ( ) was coated on wells (250 ng/100 ll/well) separately, blocked. HRP-anti-human IgG was added and bound complex was detected by
ABTS. (B) Purified human IgG (0–100 ng/100 ll/well) and a fixed concentration of CRP (250 ng/100 ll/well) was coated on a 96-well ELISA plate.
HRP–Protein A was added separately and processed as described in Section 2.
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confirming their electrophoretic homogeneity with small but
distinct differences in mobility. Single subunit in SDS–PAGE
(Fig. 1D) supported again their purity with variations in their
mol. wt (27–31 kDa) indicating the presence of molecular
variations in different clinical samples.
DIG enzyme-immunoassay clearly demonstrated that out of
eight CRPs (Table 1), seven are glycosylated (Fig. 1E).
CRPbrain abscess (column 7) showed no reactivity indicating the
absence of carbohydrates. Among seven glycosylated CRPs, six
of them are differentially sialylated (Fig. 1F, columns 2–6 and
8). CRPrheumatic fever (column 1) showed no color indicating
absence of sialylation. Notably, the extents of glycosylation
and sialylation prominently differed from each other, as evident
from the intensities of the spots by densitometric scanning.
The presence of linkage specific sialic acid in these six
sialylated CRPs was determined with the help of Sambucus
nigra agglutinin (SNA) (Fig. 1G) and Maackia amurensis ag-
glutinin (MAA) (Fig. 1H). CRPalcoholic hepatitis, CRPsnakebite and
CRPRA showed positive reactivity with SNA (Fig. 1G, col-
umns 1, 4, and 5) indicating existence of a2-6 linked sialic
acids. In contrast, CRPacute appendicitis, CRPlivermalignancy and
CRPmeningitis were reactive to MAA (Fig. 1H, columns 2, 3 and
6) suggesting the presence of a2-3 linked sialic acids.
A representative gel picture shows a shift in the mobility of
CRPacute appendicitis, a glycosylated CRP, indicating decrease in
the molecular mass of three kDa after N-glycosidase F-
digestion (Fig. 1I). No change in the electrophoretic mobility
was observed following O–glycosidase digestion indicating
that CRP is glycosylated possibly through N- and not
O-linkage.3.2. CRP binds to Protein A
The exponential titration curve of the binding of Protein A
with increasing concentration (0–4 lg/ml) of CRP is shown in
Fig. 3, inset. The curve reached a plateau at about 2.5 lg/ml.
This is the first demonstration of binding ofCRPwith ProteinA.
To exclude the interference of human IgG in CRP–Protein
A binding, a control ELISA was carried out, which clearly
Fig. 4. Comparative analysis of binding of three CRPs with SpA. (A)
A fixed number (OD600nm ¼ 0:5) of bacterial cells were incubated with
different concentrations of (0–50 lg/ml) of FITC conjugated
CRPmeningitis, CRPbrain abscess and CRPVL and analyzed by flow cy-
tometry (Section 2.6). (B) A representative profile of flow cytometric
analysis to compare the percentage binding of bacterial cells
(OD600nm ¼ 0:5) to a fixed concentration (10 lg/ml) of FITC-
CRPmeningitis (1), CRPbrain abscess (2) and CRPVL (3), where (4) repre-
sents corresponding negative control.
T. Das et al. / FEBS Letters 576 (2004) 107–113 111showed that contaminating amount of IgG, if any, contributes
very insignificantly to the Protein A binding as compared to
CRP–Protein A binding (Fig. 2B).
3.3. Different molecular variants of CRP showed differential
reactivity with Protein A
To assess the role of structural differences of CRP in Protein
A binding, an ELISA was carried out using fixed amount of
fourteen molecular variants of CRP purified from fourteen
different clinical samples. All eleven glycosylated CRPs ex-
hibited variable degree of Protein A binding (Fig. 3). An 18-
fold higher binding was observed with CRPmeningitis than that
of CRPRA. The binding decreased as follows: CRPmeningitis
 CRPTB ¼ CRPsnakebiteo CRPVL¼ CRPacute appendicitis >
CRPosteogenic sarcoma ðpleural fluidÞ > CRPALL ¼ CRPRA again
suggesting the contribution of structural variations induced in
different molecular variants of CRP in Protein A binding.
CRPalcoholic hepatitis, CRPrheumatic fever and CRPlivermalignancy
showed minimal binding with Protein A at this concentration.
3.4. Binding of CRP with Protein A is not related to glycosylation
Although eight glycosylated CRPs (Fig. 3, columns 1–8)
showed small amount of Protein A binding as compared to
three non-glycosylated CRPs (CRPosteogenic sarcoma, CRPbrain abscess
and CRPburn), other two glycosylated CRPs (CRPTB and
CRPsnakebite) showed almost the same extent of Protein A
binding as the non-glycosylated CRPbrain abscess and
CRPosteogenic sarcoma: However, CRPmeningitis (glycosylated) and
CRPburn (non-glycosylated) exhibited higher extent of Protein
A binding. Thus, apparently, no correlation was observed be-
tween the extents of glycosylation with the extents of Protein A
binding (Fig. 3).
3.5. Binding of Protein A with CRP is calcium independent
Although calcium plays a very important role in the binding
of CRP with its classical ligand (PC), the extent of the binding
of CRP with Protein A remained the same in the absence and
presence of calcium, suggesting CRP–Protein A binding is
independent of calcium and probably not through the PC
binding site on CRP molecule. In contrast to Protein A-
binding property, no significant difference in binding of these
molecular variants with PC was observed. As expected, with
increasing Ca2þ concentration, the PC-binding increased and
reached a plateau at higher concentrations with a half maximal
binding at 3 mM confirming the dependence of Ca2þ on PC-
binding of all the molecular variants of CRP.
3.6. Protein A and PC binding epitopes on CRP are different
Inhibition studies on CRP–Protein A binding, using very
high and wide range of concentrations of PC (50–150 mM),
were carried out by incubating CRP with PC before and after
coating on an ELISA plate. Alternatively, PC was added to-
gether with Protein A in CRP coated plate and the extent of
binding of Protein A to CRP was compared with that in the
absence of PC. In all these cases, the binding remained unal-
tered reflecting that PC and Protein A were not competing for
the same site on CRP.
3.7. CRP binds to S. aureus Protein A
The increasing concentrations (OD600 nm ¼ 0:2–0.7) of bac-
terial cells, known to contain high amount of Protein A ontheir cell surface, showed a steadily increased (between 50%
and 100%) binding with 125ICRPs. Both glycosylated
(CRPmeningitis) and non-glycosylated (CRPbrain abscess) CRPs
showed strong binding with these cells. CRPs pre-incubated
with PC also showed more or less unaltered binding indicating
that the PC moiety, present on the bacterial cells, is not in-
terfering in this interaction reconfirming that PC and Protein
A binding sites are different on CRP.
3.8. FACS analysis confirmed the binding of CRP with SpA
The binding of FITC-CRP with bacterial cells was further
corroborated by FACS analysis. Three representatives high
(CRPmeningitis), medium (CRPbrain abscess) and low (CRPVL)
Protein A binding CRPs, as detected by ELISA (Section 3.3,
Fig. 3), were selected. A wide variation in binding with these
CRPs was observed with a fixed concentration of the bacteria
(Fig. 4A). The amount of CRP needed for maximum (90%)
binding differed, the concentration being 15 lg/ml for
CRPmeningitis and 25 lg/ml for CRPbrain abscess whereas, CRPVL
did not attain to that point even at 50 lg/ml. No significant
binding was observed below 1 lg/ml concentration. Maximum
variation in binding was observed with 10 lg/ml CRPs (Fig.
4B), considered as early state of acute phase reaction, % of
cells showing binding being 89%, 49% and 5% with
CRPmeningitis (1), CRPbrain abscess (2) and CRPVL (3), respec-
tively, with respect to negative control (4).
The specificity of binding of CRP with SpA was demon-
strated by two separate experiments. Initially, Protein A-in-
cubated with either 125ICRPs or FITC-CRPs were allowed to
Fig. 5. Scatchard analysis of CRP–Protein A and CRP–PC binding. (A) Fixed amount of Protein A–Sepharose () or PC–Sepharose (j) (20 ll/tube
of each) were separately incubated with increasing concentrations of 125ICRPmeningitis (specific radioactivity 2.5 109 cpm/mg). Bound radioactivity
was plotted against the volume (ll) of 125ICRP. (B) Scatchard plot, in which bound/free was plotted against the amounts of bound CRP. The
apparent association constant was calculated from the slope of the Scatchard plot.
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of 45% and 30% binding of pre-incubated 125ICRPs and
FITC-CRPs with bacteria reflects its specificity towards
Protein A.
3.9. Comparison of affinity constants between CRP–Protein A
and CRP–PC binding
The plot of binding of 125I-labeled CRP with Sepharose–
Protein A or Sepharose–PC separately (Fig. 5A) demonstrated
that the binding reached almost to saturation about 75 ll of
added 125ICRP in both the cases but to different levels. Ap-
parent binding constants (Ka) of CRP with Protein A and PC,
calculated from the slopes of Scatchard plots, (Fig. 5B)
were found to be 4.9 106 and 1.9 107 M1, which corre-
spond to dissociation constants (Kd) of 205 and 53 nM,
respectively.4. Discussion
The marked elevation of CRP levels following infection,
tissue injury or a variety of inflammatory responses strongly
suggests that CRP is actively involved in host defense
mechanism [20]. Due to its extensive clinical use, for rapid
1000–3000-fold rise in serum concentration in an underlying
inflammatory process, human CRP drew wide attention. In
spite of in vitro demonstration of the involvement of CRP in
an array of biological events like complement activation,
opsonization, macrophage activation, selective deposition at
the site of tissue damage and binding to several biological
macromolecules [21], their precise physiological role remains
to be elucidated.
The major achievements of the current investigation includes
(i) purification, characterization and establishment of the in-
duction of glycosylated molecular variants due to their struc-
tural variation of a panel of CRPs from several pathological
conditions to introspect the CRP–Protein A interaction (Table
1, Fig. 1), (ii) demonstration of specific differential binding of
Protein A (both as free and cell surface bound) to fourteen
different glycosylated and non-glycosylated CRPs (Figs. 3 and
4), (iii) confirmation of no significant role of calcium and oli-
gosaccharide moieties present on CRP in the interaction of
CRP–Protein A binding (Figs. 3 and 4) and finally (iv) es-
tablishing two separate binding sites of Protein A and PC,
thereby, demonstrating conclusively Protein A as a unique li-
gand for CRP.Purified CRPs not only specifically bind to Protein A but
also exhibit variable extents of binding as evidenced by several
approaches (Figs. 3,4). Binding parameters using free Protein
A and cell surface bound Protein A, as detected by ELISA
(Fig. 3), FITC-CRP (Fig. 4) or 125I-CRP (Fig. 5) convincingly
demonstrated this specific interaction. Therefore, free or
bound Protein A, either conjugated with Sepharose beads or
cell surface, showed similar binding with CRP molecules in-
dicating Protein A as a true ligand for CRP. The specificity of
the interaction was again confirmed by inhibition of binding
using CRP pre-incubated with saturable amount of free Pro-
tein A.
Notably, CRPs from different sources showed different ex-
tent of binding with Protein A (Fig. 3). CRPVL showed small
binding (5%) with SpA at 10 lg/ml concentration, whereas the
binding was 49% and 89% with the same concentrations of
CRPbrain abscess and CRPmeningitis. However, at higher concen-
trations >25 lg/ml, SpA binding reaches to a plateau for
CRPbrain abscess and CRPmeningitis, while binding with CRPVL
was still much smaller 30%. Therefore, it may be envisaged
that different molecular variants of CRP possess variable ca-
pability of binding with bacteria through Protein A depending
on their concentration in serum, severity of that particular
disease and requirement for neutralization. Thus, it may be
postulated that the CRP–Protein A interaction is a general
phenomenon for all molecular variants of CRP and the
binding epitope for Protein A is differentially expressed with
variable capacity on different disease-induced CRPs.
The presence and nature of the attached oligosaccharides on
glycoproteins is known to influence many biological functions.
Notably, the interaction of CRP–Protein A is independent of
induction of glycosylation on CRP (Figs. 3 and 4), indicating
that the structural modification due to glycosylation have no
impact on CRP–Protein A binding. These findings suggest that
the binding site for Protein A and the glycosylation site are
possibly present in two different regions on CRP molecule
reflecting flexibility of CRP molecule to interact with various
microbes. Incidentally, like CRP, carbohydrate moieties of
IgG present in Fc region also do not contribute to SpA binding
[22].
Comparison of the binding characteristics of CRP with
Protein A and its universal ligand, PC, indicates that Ca2þ ion,
an essential component for CRP–PC binding, is not required
for CRP–Protein A interaction suggesting that the Protein A
binding site does not undergo the calcium induced confor-
mational change. Moreover, CRP–Protein A binding is not
T. Das et al. / FEBS Letters 576 (2004) 107–113 113modulated by the PC binding as demonstrated by ELISA,
where the CRP–Protein A binding could not be inhibited by
saturable amount of PC suggesting existence of completely two
different regions on CRP and possibly these two sites remain
accessible for both these ligands PC and Protein A. Earlier
molecular modeling study clearly indicated that PC binding
site and glycosylation site are present in two opposite sides of
the CRP molecule [11]. It would be interesting to build mo-
lecular model of CRP–Protein A complex to identify the lo-
cation of Protein A binding. These observations have far
reaching application, as CRP, using its both arms (Protein A
and PC binding sites), will be able to bind to infective mole-
cules for their clearance. Although CRP has affinity for both
PC and Protein A, it showed higher affinity for PC (Fig. 5)
consistent with earlier widely known anti-streptococcal activity
of CRP [23].
The interaction of CRP with SpA further confirms the
presence of a novel ligand, the Protein A. This binding opens a
new avenue for identifying the biological role of CRP, where
CRP simultaneously may perform its protective role by bind-
ing to both PC and Protein A on infective organisms. These
observations deserve attention for understanding the patho-
physiological role of CRP in the recognition, clearance and
destruction of infectious organisms by the immune system.
To the best of our knowledge, this is the first report that
describes the unique ability of disease-induced molecular
variants of human CRP to bind differentially with Protein A,
an important cell surface component of microorganisms, thus
playing its anti-infective and anti-microbial roles [3] through
this new ligand for combating various microorganisms by
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